SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-20-065134
Filing Date
2020-05-22
Accepted
2020-05-22 08:40:20
Documents
5
Effectiveness Date
2020-05-22

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm2020720d1_defa14a.htm DEFA14A 36773
2 GRAPHIC image_001.jpg GRAPHIC 21670
3 GRAPHIC image_002.jpg GRAPHIC 23551
4 GRAPHIC image_003.jpg GRAPHIC 24253
5 GRAPHIC image_004.jpg GRAPHIC 5209
  Complete submission text file 0001104659-20-065134.txt   141212
Mailing Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014
Business Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014 212-554-4366
Checkpoint Therapeutics, Inc. (Filer) CIK: 0001651407 (see all company filings)

IRS No.: 472568632 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38128 | Film No.: 20903750
SIC: 2834 Pharmaceutical Preparations